Kardigan Raises $400M in Upsized IPO, Pricing Shares at $16
Tom Rudovsky · Reported by Reuters
More coverage: Healthcare
Sentiment
Positive
Importance
9
Price
0
Mkt Cap
0
52W Low
0
52W High
0
52W Position
Off High
Rel. Volume
Market data snapshot near publication time
Summary
Heart drug developer Kardigan successfully raised $400 million in an upsized initial public offering, selling 25 million shares at $16 each, the top of its target range. This significant capital infusion will fund the clinical development of its three late-stage experimental therapies, including treatments for genetic dilated cardiomyopathy and calcific aortic valve stenosis. The strong investor demand, evidenced by the upsized offering and top-range pricing, provides crucial funding for this clinical-stage biotech ahead of its Nasdaq debut on Thursday.
This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.
Price Chart
KARD - Latest Insights
KARD
Aug 11, 2026, 7:10 AM EDT
Price at Filing:
$20.41
Real-time Price:
$14.79
Change:
-$5.62 (-28%)
Market Cap:
$1.383B
KARD
Aug 11, 2026, 7:00 AM EDT
Price at Filing:
$20.41
Real-time Price:
$14.79
Change:
-$5.62 (-28%)
Market Cap:
$1.383B
KARD
Aug 11, 2026, 7:00 AM EDT
Price at Filing:
$20.41
Real-time Price:
$14.79
Change:
-$5.62 (-28%)
Market Cap:
$1.383B
KARD
Jun 29, 2026, 4:05 PM EDT
Price at Filing:
$25.90
Real-time Price:
$14.79
Change:
-$11.11 (-43%)
Market Cap:
$1.383B
KARD
Jun 25, 2026, 4:00 PM EDT
Price at Filing:
$22.58
Real-time Price:
$14.79
Change:
-$7.79 (-34%)
Market Cap:
$1.383B